MEDICINAL cannabis and health products company Bod has announced it has entered a research collaboration with the University of Sydney Lambert Initiative for the development of a compound marker required in the Phase I clinical trial of Bod's sublingual cannabis wafer.
The Lambert Initiative was formed in 2015 following a $33.7m donation from the Lambert family to the university for research into therapeutic uses of medicinal cannabis.
The grant will cover around 50% of the total project costs.
Bod says the Phase I Clinical trial continues with initial results expected in Nov 2018.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Sep 18
